PT  - JOURNAL ARTICLE
AU  - Fasihul Khan
AU  - Iain Stewart
AU  - Gauri Saini
AU  - Karen A Robinson
AU  - Gisli Jenkins
TI  - A systematic review and individual participant data meta-analysis of MMP-7 and outcomes in idiopathic pulmonary fibrosis
AID  - 10.1183/13993003.congress-2021.PA395
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA395
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA395.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA395.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by collagen deposition and poor prognosis. Matrix-metalloproteinase-7 (MMP-7) degrades extracellular matrix components and has been widely studied as a biomarker in IPF. Through systematic review and individual participant data (IPD) meta-analysis, we evaluated the prognostic potential of MMP-7.Electronic database (MEDLINE, Embase and preprint servers) searches were updated in November 2020 for prospective studies of untreated IPF stratified by at least one predefined biomarker. The primary outcome was overall mortality, with secondary outcomes including disease progression, defined as ≥10% relative FVC decline or death within 12 months. A two-step random effects IPD meta-analysis of MMP-7 was adjusted for age, sex, smoking history and baseline FVC.A total of 12 MMP-7 studies were identified, of which IPD was available for nine studies and 1664 participants. Baseline MMP-7 levels were associated with mortality (adjusted hazard ratio 1.23 per SD increase, 95%CI 1.02;1.48, I2=68.8%) and disease progression (adjusted odds ratio 1.27 per SD increase, 95%CI 1.11;1.46, I2=5.9%).In summary we demonstrate MMP-7 can predict important clinical outcomes in IPF and should be considered for implementation as a prognostic tool at the point of diagnosis, particularly where lung function is unvailable.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA395.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).